"My hope is to make the fruits of medical innovation accessible to more people globally regardless of their level of income, nationality, or background."
The main reason I stepped out of a stable career in academia to start PCL in a field as fiercely competitive as medical devices is the strong market potential our technology showed. Although the immuno-diagnostics market has been around for a while, innovation is slow, and breakthroughs are, if anything, rare. For example, EIA technology, which PCL specializes in, was first developed 46 years ago and remains standard in an industry estimated to be worth 30 trillion US dollars globally.
Within the field of EIA technology, a US-based company named Abbott has been able to develop techniques that enhance the sensitivity of medical diagnostics in line with government regulations, namely CLIA (Clinical Laboratory Improvement Amendments). In spite of these improvements, it has been hard to get the sensitivity of medical testing devices up to a point where multiple illnesses can be diagnosed at once (known as multiplex diagnosis).
As a Dongguk University professor, I leveraged research on AIDS transmission I conducted as a PhD candidate at Cornell to create a system for multiplex diagnosis based on aptamer-based protein biochips which are then analyzed for disease detection. The result of this work is none other than the 3D SG CAP solution (3D Sol-gel Capturing System, Multiplex Immunodiagnostic Platform), which can diagnose various diseases simultaneously while keeping the biomarker stable and integrated within the biochip.
Our solution has been reviewed by the nationally designated research laboratories of over thirty countries across the world where it has been registered and patented. PCL was founded based on such original technology which we co-developed with German-based Scienion AG. Since its introduction in a popular web-based American magazine back in 2008, the 3D SG CAP solution has made much headway as a game-changer in immuno-diagnostics.
Recently, PCL has reached a major milestone by acquiring multiplex immuno-diagnosis licenses for high-risk viruses in both Europe and South Korea, thus making us a leading player in the industry. The team at PCL is working tirelessly to pave the way for more enhancements in in-vitro diagnostics. We will not stop in our mission to make this premium technology accessible to more people in the world regardless of income or background. It is thus in this spirit of goodwill that I ask for all your support and encouragement. Thank you.